Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company’s Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders.

Dear Fellow Stockholders,

I am delighted to join Longeveron at what I believe is an extraordinary time for the Company and our stem cell therapy, laromestrocel (Lomecel-B). Longeveron is progressing through a significant inflection point in the Company’s history.

After taking on the CEO role in February, we embarked on two immediate critical tasks: a comprehensive review of the Company’s assets, development programs and strategic plan, and attracting new investment capital. Following this review, we have taken decisive steps to reposition the Company for long-term value creation, sharpen our strategic focus, and align our development and capital strategy with the most impactful near-term catalysts. With this reorientation, we were able to successfully attract new investment capital from several of the premier investment funds in the life sciences space, Coastlands Capital, Janus Henderson Investors, Logos Capital and Kalehua Capital. In 2026, we are approaching a series of potentially transformative milestones that we believe have the potential to redefine the trajectory of our business.

Today, I am pleased to provide an update on our strategy, recent progress, and key priorities for through the rest of this year.

Strategic Transformation and Corporate Evolution

In early 2026, we initiated a strategic repositioning of Longeveron designed to maximize stockholder value while maintaining disciplined capital allocation. We have transitioned toward a more capital-efficient model with an increased focus on securing strategic licensing partnerships for laromestrocel.

This evolution reflects both the strength of our clinical data and the growing external validation of our programs. We believe that leveraging the commercial infrastructure, capital resources, and global reach of established pharmaceutical partners represents the most efficient pathway to unlock the full value of our assets.

At the same time, we are focusing our development activities to prioritize our most important near-term catalyst: the data readout from our Phase 2b clinical trial (ELPIS II) in Hypoplastic Left Heart Syndrome (HLHS), expected in August of this year. This disciplined prioritization has enabled us to extend our operating runway while maintaining focus on value-driving milestones.

Schreibe Deinen Kommentar